MoonLake Immunotherapeutics (MLTX) News Today $43.81 +2.34 (+5.64%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced UponJanuary 17 at 6:49 PM | seekingalpha.comGoldman Sachs Upgrades MoonLake Immunotherapeutics (MLTX)January 17 at 1:47 PM | msn.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up - Here's WhyMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up - Still a Buy?January 17 at 12:45 PM | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Upgraded at The Goldman Sachs GroupThe Goldman Sachs Group upgraded MoonLake Immunotherapeutics from a "neutral" rating to a "buy" rating and upped their price target for the company from $62.00 to $82.00 in a research report on Friday.January 17 at 4:38 AM | marketbeat.comHC Wainwright Reaffirms Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)January 12, 2025 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Rating of "Moderate Buy" from AnalystsJanuary 12, 2025 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has been given an average rating of "Moderate Buy" by the eight ratings firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has gJanuary 12, 2025 | marketbeat.comMoonLake Immunotherapeutics: Strategic Expansion in Clinical Trials Positions Sonelokimab for Market GrowthJanuary 11, 2025 | markets.businessinsider.comMoonLake Immunotherapeutics: Promising Prospects and Market Expansion with SonelokimabJanuary 10, 2025 | markets.businessinsider.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a report on Friday.January 10, 2025 | marketbeat.comMoonLake Immunotherapeutics Poised for Transformational Growth: Buy Rating Affirmed on Strategic Clinical Expansion and Strong Financial PositionJanuary 9, 2025 | markets.businessinsider.comMoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimabJanuary 8, 2025 | globenewswire.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Strong Trading Volume - Here's WhyMoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Strong Trading Volume - Time to Buy?January 6, 2025 | marketbeat.comIs There An Opportunity With MoonLake Immunotherapeutics' (NASDAQ:MLTX) 27% Undervaluation?January 1, 2025 | uk.finance.yahoo.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Position Raised by State Street CorpState Street Corp boosted its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 96.2% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 87,637 shares of the company's stock after acquiring an addDecember 30, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 5.1% - Still a Buy?MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading 5.1% Higher - Should You Buy?December 26, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Down 3.2% - What's Next?MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 3.2% - What's Next?December 20, 2024 | marketbeat.comMoonLake Immunotherapeutics Announces Board Changes and IncentivesDecember 18, 2024 | tipranks.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has earned an average rating of "Moderate Buy" from the eight analysts that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a sDecember 18, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 7.9% - Here's What HappenedMoonLake Immunotherapeutics (NASDAQ:MLTX) Trading 7.9% Higher - Time to Buy?December 17, 2024 | marketbeat.comStifel Nicolaus Sticks to Its Buy Rating for MoonLake Immunotherapeutics (MLTX)December 17, 2024 | markets.businessinsider.comWellington Management Group LLP Sells 180,599 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Wellington Management Group LLP reduced its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 48.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 192,058 shares of the company's stock after sellingDecember 16, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 96.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The instituDecember 16, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Down 5.6% - Here's What HappenedMoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 5.6% - Should You Sell?December 13, 2024 | marketbeat.comOppenheimer Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)December 12, 2024 | markets.businessinsider.comJefferies Remains a Buy on MoonLake Immunotherapeutics (MLTX)December 12, 2024 | markets.businessinsider.comBuy Rating for MoonLake Immunotherapeutics Driven by Sonelokimab’s Potential in HS and PsA TreatmentDecember 11, 2024 | markets.businessinsider.com15,000 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Acquired by Erste Asset Management GmbHErste Asset Management GmbH bought a new stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 15,000 shares of the company's stock, valued at approximately $741,0December 4, 2024 | marketbeat.comFmr LLC Purchases 1,306,215 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Fmr LLC boosted its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 35.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,950,224 shares of the company's stock after acquiring an additiDecember 2, 2024 | marketbeat.comWestfield Capital Management Co. LP Buys 49,733 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Westfield Capital Management Co. LP increased its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 4.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,167,358 shares of the company's stock after purchaNovember 25, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of "Moderate Buy" by AnalystsShares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the ten analysts that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assignNovember 23, 2024 | marketbeat.comMoonLake Immunotherapeutics’ Promising SLK Therapy Forecasts Strong Market Performance and Stock PotentialNovember 22, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics: A Somewhat Complicated StoryNovember 21, 2024 | seekingalpha.comVictory Capital Management Inc. Grows Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)Victory Capital Management Inc. raised its position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 24.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 217,839 shares of tNovember 21, 2024 | marketbeat.comMoonLake Immunotherapeutics management to meet with OppenheimerNovember 19, 2024 | markets.businessinsider.comPromising Outlook for MoonLake’s Sonelokimab in Psoriatic Arthritis TreatmentNovember 15, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics’ Promising Phase 3 Trials for PsA Treatment Drives Buy RatingNovember 15, 2024 | markets.businessinsider.comBuy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Advancements and Strong Market PotentialNovember 14, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $100.00 price objective on shares of MoonLake Immunotherapeutics in a report on Thursday.November 14, 2024 | marketbeat.comMoonLake Immunotherapeutics announces first patients screened in IZAR programNovember 14, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)November 14, 2024 | markets.businessinsider.comBuy Rating for MoonLake Immunotherapeutics Driven by Clinical Advancements and Market OpportunitiesNovember 11, 2024 | markets.businessinsider.comStrategic Initiatives and Financial Stability Propel MoonLake Immunotherapeutics Towards Promising Market PositionNovember 9, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics Reports Q3 2024 Financial ResultsNovember 9, 2024 | tipranks.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a research report on Friday.November 8, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Announces Earnings ResultsMoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.12). During the same quarter in the prior year, the firm posted ($0.18) earnings per share.November 8, 2024 | marketbeat.comMoonLake Immunotherapeutics: Strategic Growth and Financial Stability Drive Buy RatingNovember 7, 2024 | markets.businessinsider.comPromising Growth Prospects for MoonLake Immunotherapeutics: Buy Rating Supported by Strategic Developments in HS and PsA ProgramsNovember 7, 2024 | markets.businessinsider.comBrokers Set Expectations for MLTX Q3 EarningsMoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities researchers at Wedbush issued their Q3 2024 earnings per share (EPS) estimates for MoonLake Immunotherapeutics in a research report issued to clients and investors on Monday, November 4th. Wedbush analyst Y. Zhong anticipates thatNovember 7, 2024 | marketbeat.comPromising Results for MoonLake’s Sonelokimab in HS Treatment Drive Buy RatingNovember 6, 2024 | markets.businessinsider.com Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address MLTX Media Mentions By Week MLTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLTX News Sentiment▼0.590.72▲Average Medical News Sentiment MLTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLTX Articles This Week▼93▲MLTX Articles Average Week Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SRPT News Today QGEN News Today PCVX News Today ASND News Today ROIV News Today RVMD News Today LNTH News Today BPMC News Today BBIO News Today LEGN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLTX) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MLTX Stock Alerts